LITAF is a potential tumor suppressor in pancreatic cancer

作者：Zhou, Yuan; Huang, Jing; Yu, Xi; Jiang, Xin; Shi, Yaoyao; Weng, Yuanyuan; Kuai, Yue; Lei, Lizhen; Ren, Guoping; Feng, Xiaowen; Zhong, Guoping; Liu, Qingmeng; Pan, Hongyang; Zhang, Xinxia; Zhou, Ren; Lu, Caide^*

来源：Oncotarget, 2018, 9(3): 3131-3142.

DOI：10.18632/oncotarget.23220

• lipopolysaccharide-induced tumor necrosis factor-a factor (LITAF)
• pancreatic cancer
• promoter methylation
• tumor suppressor gene

Early diagnosis of pancreatic cancer, one of the most deadly cancers with low survival rates, is difficult, and effective biomarkers are urgently needed. Lipopolysaccharide-induced tumor necrosis factor-a factor (LITAF) has been recently proposed as a potential tumor suppressor gene in several types of cancer. Here, we analyzed the biological function of LITAF in pancreatic cancer. The LITAF gene and protein levels were decreased in pancreatic tumor tissues compared with their paired adjacent non-cancerous tissues. In addition, patients with the lower LITAF protein expression had lower disease-free survival rates. The decreased LITAF expression correlated with LITAF promoter hypermethylation in pancreatic cancer cells and tissues. Moreover, promoter demethylation dose-dependently increased the LITAF transcription. Importantly, LITAF demethylation suppressed proliferation and cell cycle progression, and enhanced apoptosis of pancreatic cancer cells. Together, our results indicate that LITAF functions as a tumor suppressor gene in pancreatic cancer cells, and might serve as a novel biomarker for early diagnosis of pancreatic cancer.

• 出版日期2018-1-9
• 单位浙江大学; 宁波大学